Identification of Epigenetic Methylation Signatures With Clinical Value in Crohn's Disease

Overview

Journal Clin Transl Gastroenterol

Specialty Gastroenterology

Date 2019 Oct 31

PMID 31663908

Citations 17

Authors

Ines Moret-Tatay

Elena Cerrillo

Esteban Saez-Gonzalez

David Hervas

Marisa Iborra

Juan Sandoval

Enrique Buso

Luis Tortosa

Pilar Nos

Belen Beltran

Affiliations

Soon will be listed here.

Abstract

Introduction: DNA methylation is an epigenetic mechanism that regulates gene expression and represents an important link between genotype, environment, and disease. It is a reversible and inheritable mechanism that could offer treatment targets. We aimed to assess the methylation changes on specific genes previously associated with Crohn's disease (CD) and to study their possible associations with the pathology.

Methods: We included 103 participants and grouped them into 2 cohorts (a first [n = 31] and a second validation [n = 72] cohort), with active CD (aCD) and inactive CD (iCD) and healthy participants (CTR). DNA was obtained from the peripheral blood and analyzed by the Agena platform. The selected genes were catalase (CAT), α-defensin 5 (DEFA5), FasR, FasL, tumor necrosis factor (TNF), TNFRSF1A, TNFRSF1B, PPA2, ABCB1, NOD2, PPARγ, and PKCζ. We used the elastic net algorithm and R software.

Results: We studied 240 CpGs. Sixteen CpGs showed differential methylation profiles among aCD, iCD, and CTR. We selected for validation those with the greatest differences: DEFA5 CpG_11; CpG_13; CAT CpG_31.32; TNF CpG_4, CpG_12; and ABCB1 CpG_21. Our results validated the genes DEFA5 (methylation gain) and TNF (methylation loss) with P values < 0.001. In both cases, the methylation level was maintained and did not change with CD activity (aCD vs iCD). The subanalysis comparison between aCD and iCD showed significant differential methylation profiles in other CpGs: TNF, FAS, ABCB1, CAT, and TNFRS1BF genes.

Discussion: The methylation status of DEFA5 and TNF genes provides a signature biomarker that characterizes patients with CD and supports the possible implication of the environment and the immune system in CD pathogenesis.

Citing Articles

Multi-omics pan-cancer analysis reveals the prognostic values and immunological functions of PPA2, with a spotlight on breast cancer.

Zhang J, Yang B, Li L, Xu H, Wang B, Yi Z Front Immunol. 2024; 15:1435502.

PMID: 39176095 PMC: 11338811. DOI: 10.3389/fimmu.2024.1435502.

Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review.

Plaza J, Minguez A, Bastida G, Marques R, Nos P, Poveda J Int J Mol Sci. 2024; 25(7).

PMID: 38612528 PMC: 11012229. DOI: 10.3390/ijms25073717.

Increased CpG methylation at the CDH1 locus in inflamed ileal mucosa of patients with Crohn disease.

de Ponthaud C, Abdalla S, Belot M, Shao X, Penna C, Brouquet A Clin Epigenetics. 2024; 16(1):28.

PMID: 38355645 PMC: 10865720. DOI: 10.1186/s13148-024-01631-z.

Catalase inhibition can modulate the ability of peripheral blood T cells to undergo apoptosis in Crohn's disease.

Moret-Tatay I, Nos P, Iborra M, Rausell F, Beltran B Clin Exp Immunol. 2024; 217(1):45-56.

PMID: 38247555 PMC: 11188543. DOI: 10.1093/cei/uxad134.

Mucosal DNA methylome alteration in Crohn's disease: surgical and non-surgical groups.

Ahmad S, Sands M, Greenberg E, Tangen L, Huang J, Irudayaraj J Front Genet. 2023; 14:1244513.

PMID: 38046046 PMC: 10691104. DOI: 10.3389/fgene.2023.1244513.

References

Liu J, van Sommeren S, Huang H, Ng S, Alberts R, Takahashi A . Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet. 2015; 47(9):979-986. PMC: 4881818. DOI: 10.1038/ng.3359. View

Gomollon F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay J . 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis. 2016; 11(1):3-25. DOI: 10.1093/ecco-jcc/jjw168. View

Eder P, Lykowska-Szuber L, Krela-Kazmierczak I, Stawczyk-Eder K, Iwanik K, Majewski P . Disturbances in apoptosis of lamina propria lymphocytes in Crohn's disease. Arch Med Sci. 2016; 11(6):1279-85. PMC: 4697047. DOI: 10.5114/aoms.2015.54203. View

Li Yim A, Duijvis N, Zhao J, de Jonge W, DHaens G, Mannens M . Peripheral blood methylation profiling of female Crohn's disease patients. Clin Epigenetics. 2016; 8:65. PMC: 4897922. DOI: 10.1186/s13148-016-0230-5. View

Bryant R, Winer S, Travis S, Riddell R . Systematic review: histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? An IOIBD initiative. J Crohns Colitis. 2014; 8(12):1582-97. DOI: 10.1016/j.crohns.2014.08.011. View

Taman H, Fenton C, Hensel I, Anderssen E, Florholmen J, Paulssen R . Genome-wide DNA Methylation in Treatment-naïve Ulcerative Colitis. J Crohns Colitis. 2018; 12(11):1338-1347. PMC: 6236200. DOI: 10.1093/ecco-jcc/jjy117. View

Holliday R . Epigenetics: a historical overview. Epigenetics. 2007; 1(2):76-80. DOI: 10.4161/epi.1.2.2762. View

Hu X, Deng J, Yu T, Chen S, Ge Y, Zhou Z . ATF4 Deficiency Promotes Intestinal Inflammation in Mice by Reducing Uptake of Glutamine and Expression of Antimicrobial Peptides. Gastroenterology. 2018; 156(4):1098-1111. DOI: 10.1053/j.gastro.2018.11.033. View

Lin Z, Hegarty J, Cappel J, Yu W, Chen X, Faber P . Identification of disease-associated DNA methylation in intestinal tissues from patients with inflammatory bowel disease. Clin Genet. 2010; 80(1):59-67. DOI: 10.1111/j.1399-0004.2010.01546.x. View

10.

Huang H, Fang M, Jostins L, Mirkov M, Boucher G, Anderson C . Fine-mapping inflammatory bowel disease loci to single-variant resolution. Nature. 2017; 547(7662):173-178. PMC: 5511510. DOI: 10.1038/nature22969. View

11.

Yano S, Yano N . Regulation of catalase enzyme activity by cell signaling molecules. Mol Cell Biochem. 2002; 240(1-2):119-30. DOI: 10.1023/a:1020680131754. View

12.

Satsangi J, Silverberg M, Vermeire S, Colombel J . The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006; 55(6):749-53. PMC: 1856208. DOI: 10.1136/gut.2005.082909. View

13.

Jostins L, Ripke S, Weersma R, Duerr R, McGovern D, Hui K . Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012; 491(7422):119-24. PMC: 3491803. DOI: 10.1038/nature11582. View

14.

Pereira C, Coelho R, Gracio D, Dias C, Silva M, Peixoto A . DNA Damage and Oxidative DNA Damage in Inflammatory Bowel Disease. J Crohns Colitis. 2016; 10(11):1316-1323. DOI: 10.1093/ecco-jcc/jjw088. View

15.

Ehmann D, Wendler J, Koeninger L, Larsen I, Klag T, Berger J . Paneth cell α-defensins HD-5 and HD-6 display differential degradation into active antimicrobial fragments. Proc Natl Acad Sci U S A. 2019; 116(9):3746-3751. PMC: 6397583. DOI: 10.1073/pnas.1817376116. View

16.

Van Den Boom D, Ehrich M . Mass spectrometric analysis of cytosine methylation by base-specific cleavage and primer extension methods. Methods Mol Biol. 2008; 507:207-27. DOI: 10.1007/978-1-59745-522-0_16. View

17.

Chu C . Molecular probing of TNF: From identification of therapeutic target to guidance of therapy in inflammatory diseases. Cytokine. 2016; 101:64-69. DOI: 10.1016/j.cyto.2016.08.020. View

18.

Bank S, Andersen P, Burisch J, Pedersen N, Roug S, Galsgaard J . Genetically determined high activity of IL-12 and IL-18 in ulcerative colitis and TLR5 in Crohns disease were associated with non-response to anti-TNF therapy. Pharmacogenomics J. 2017; 18(1):87-97. DOI: 10.1038/tpj.2016.84. View

19.

Cleynen I, Boucher G, Jostins L, Schumm L, Zeissig S, Ahmad T . Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet. 2015; 387(10014):156-67. PMC: 4714968. DOI: 10.1016/S0140-6736(15)00465-1. View

20.

Clark I . How TNF was recognized as a key mechanism of disease. Cytokine Growth Factor Rev. 2007; 18(3-4):335-43. DOI: 10.1016/j.cytogfr.2007.04.002. View